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ACTA NEUROPSYCHIATRICA
Oxytocin and vasopressin levels are decreased
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Objective: Impaired social functioning and autistic symptoms are
characteristics of schizophrenia. The social hormones oxytocin (OT) and
arginine-vasopressin (AVP) both modulate social interaction and therefore
may be involved in the pathogenesis of schizophrenia. We investigated
whether men with schizophrenia show altered OT and AVP levels
compared with healthy controls (HC) and whether autism symptoms are
associated with OT levels.
Methods: Forty-one men with non-acute schizophrenia and 45 matched HC
were enroled. Schizophrenia was assessed with the Positive and Negative
Syndrome Scale (PANSS). Blood samples were collected on 2 days, and
plasma OT and AVP levels were measured by ELISA immunoassay.
Results: The schizophrenia patients had significantly lower plasma OT
levels than the HC; a similar trend was found for AVP. Plasma OT levels
were associated with severe life events, fewer important attached persons,
and a higher score on the PANSS negative scale; the most dominant PANSS
items were ‘preoccupation’, ‘emotional withdrawal’, and ‘passive/apathetic
social withdrawal’.
Conclusion: These findings support an association between the social
hormones OT and AVP and schizophrenia. We suggest that OT metabolism
may be altered in schizophrenia, but other possible causes for decreased
plasma OT levels in schizophrenia patients include decreased OT synthesis,
mRNA expression, and translation. Especially the ‘autistic’ symptoms of
schizophrenia seem to be closely linked to an altered metabolism of OT, the
‘attachment’ hormone.
Significant outcomes
1. Lower plasma oxytocin (OT) and arginine-vasopressin (AVP) levels in schizophrenia patients than in
healthy controls (HC);
2. OT plasma levels associated with severe life events and fewer important attached persons; and
3. OT plasma levels associated with negative symptoms of schizophrenia.
Limitations
1. Intake of atypical antipsychotic drugs might have affected OT and AVP plasma levels.
2. Results might be gender related and cannot be transferred to female patients; and
3. OT levels in plasma should be compared with levels in cerebrospinal fluid.
Introduction
In 1908, Eugen Bleuler, who coined the term
‘schizophrenia’, described autistic symptoms as
so-called core symptoms of schizophrenia (1).
Today, the core symptoms of schizophrenia are
considered to include positive and negative symptoms
and cognitive impairment, and the autistic symptoms of
schizophrenia are indicated rather by the following
items on the Positive and Negative Syndrome Scale
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(PANSS) (2): poor attention, preoccupation, difficulty
in abstract thinking, stereotyped thinking, disturbance
of volition, and hallucinations (3). Schizophrenia often
begins with prodromal symptoms such as preoccupa-
tion and isolation. Impaired social functioning (4),
emotional deficits (5), and a reduced Theory of Mind
(6) then later characterise schizophrenia patients over
the course of the disease. It is important to gain an
understanding of impaired social functioning in
schizophrenia and the underlying neurobiological
mechanisms, because social outcomes are more
strongly affected in schizophrenia patients than voca-
tional or residential outcomes, and because real-world
social outcomes are mostly predicted by blunted affect
and passive-apathetic social withdrawal (7).
The closely related neuropeptides and social
hormones OT and AVP both modulate social
interactions in humans (8) and therefore are attractive
candidates for involvement in the pathogenesis of
schizophrenia. OT is known to facilitate ‘trust’
behaviour (9) and the ability to detect subtle
emotional cues from pictures of eyes (10), whereas
AVP seems rather to be associated with male-typical
social behaviours such as reproduction, aggression, and
territoriality (8,11). OT and AVP are synthesised in
magnocellular neurons in the paraventricular and
supraoptic nuclei of the hypothalamus and are
processed along the axonal projections to the
posterior lobe of the pituitary, where they are stored
in secretory vesicles and released into the peripheral
circulation. In addition, OT and AVP are released from
dendrites into the extracellular space, resulting not only
in local action but also in diffusion through the brain to
reach distant targets in the periphery (12).
Several studies suggest the hypothesis that
alterations in the OT and AVP system contribute to
the social deficits and disabling cognitive and
motivational impairment in patients with schizo-
phrenia and that administration of OT and AVP may
have clinical benefits. However, results are
still inconclusive: Regarding the OT system, some
studies initially reported elevated plasma OT-
neurophysin or cerebrospinal fluid (CSF) OT levels
in schizophrenia patients compared with HC (13,14),
whereas other authors found no alteration in CSF
levels in schizophrenia patients compared to HC
(15,16). Goldman et al. (17) found decreased plasma
OT only in schizophrenic patients with polydipsia
and hyponatremia: Blunted plasma OT levels in
schizophrenic patients were associated with a low
performance in a facial affect rating task. In another
study, endogenous reactivity of the OT system within
a trust-related interpersonal interaction did not show
differences between schizophrenic patients and HC,
but decreased trust-related endogenous release of OT
was associated with negative symptoms in the patient
group (18). Other recent studies gave further
evidence for an association between OT levels and
clinical symptoms in schizophrenia. OT blood levels
were inversely correlated with symptom severity in
women with schizophrenia (19), but not in men; pro-
social behaviour and higher OT levels were
correlated in both sexes (19). In a very recent
study, Rubins et al. (20) found a correlation between
higher plasma OT levels and greater positive symptom
severity. However, within another previous sample
Rubins found no significant difference in plasma OT
between acutely ill, unmedicated first-episode
schizophrenia patients and HC and no association
with clinical symptoms and cognition (21). Another
study found a negative correlation between CSF OT and
the negative PANSS subscale in male patients with
schizophrenia (16). Therefore, schizophrenia patients
might benefit from OT treatment, and the question
of a therapeutic use is gaining increasing interest.
Antipsychotic-like effects have been attributed to
endogenous OT or systemically administered OT in
several different animal models relevant to
schizophrenia (22–24), and two older clinical trials
already demonstrated therapeutic effects of OT
administration in patients with schizophrenia (25,26).
Recent studies replicated these results: The adjunctive
application of intranasal OT in 15 schizophrenia patients
significantly reduced PANSS scores, the greatest
reduction being in negative symptoms (27). Moreover,
Feifel et al. (28) reported positive effects of OT
administration on cognition in schizophrenia patients.
Modabbernia found that PANSS positive, negative, and
global symptoms improved after OT administration
(29), and Pedersen et al. (30) found that psychotic
symptoms decreased and social cognition improved
after OT administration. A single intranasal application
of OT improved performance in a higher-level social
cognition task in schizophrenia patients (31). Another
study showed that the hormone improved fear
recognition among schizophrenia patients and HC
whose baseline performance was below the median;
this improvement was regardless of the individuals’
psychiatric status, and OT did not differentially affect
emotion recognition in patients and HC in this cohort
(32). A recent study explored whether 10 or 20 IU of
intranasal OT reverses the impaired discrimination of
facial affect in schizophrenia patients and found
improved emotion recognition after 20 IU OT in
polydipsic relative to non-polydipsic patients but
worse emotion recognition after 10 IU in both patient
groups (33).
Several authors have found evidence of AVP altera-
tions in schizophrenia patients, although first studies
could not find differences in CSF AVP between
schizophrenia patients and HC (13). However,
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in schizophrenic patients with polydipsia. Neuroleptic
drugs normalised psychotic symptoms and AVP plasma
levels in schizophrenia patients (35,36). In contrast, very
recent studies found lower plasma AVP levels in
schizophrenia patients than in HC (20,21); higher AVP
levels were associated with greater positive symptom
severity in female patients (21). Rubins et al. even found
lower AVP levels in relatives of schizophrenia patients
and therefore suggested AVP levels as a potential marker
of biological vulnerability for psychosis (20). Some
evidence for a therapeutic potential of AVP in
schizophrenia patients was given by Bramilla et al. and
Hosseini et al., both of whom found a positive effect
of intranasal administration of the AVP analogue
desmopressin on (especially negative) symptoms
(37,38). Moreover, these results are underlined by
results on AVP-deficient Brattleboro rats. These rats
have many features of schizophrenia, and these features
can be improved by antipsychotic administration (39,40).
Taken together, many studies report about AVP
and OT system alterations in schizophrenia and about
the therapeutic use of AVT and OT. Because results
are still controversial and inconsistent, more
investigations are needed to understand the associ-
ation between alterations in this hormone system and
schizophrenia.
Aim of the study
Most studies about alterations in the OT and AVP
system in schizophrenia patients are in acute patients,
and few studies evaluate the association between
clinical characteristics and AVP in schizophrenia and
the correlation with OT. Therefore, we investigated
whether young men with schizophrenia show alterations
in both plasma OT and plasma AVP levels compared
with HC and evaluated whether male schizophrenia
patients with higher scores for ‘autism’ PANSS items
show lower OT and AVP levels than male schizo-
phrenia patients without such ‘autism’ symptoms.
Methods
Setting/participants
Forty-one men with a Diagnostic and Statistical
Manual of Mental Disorders-IV (DSM-IV) (41)
diagnosis of schizophrenia, confirmed by a Struc-
tured Clinical Interview for DSM-IV, were enroled
and compared with 45 HC 1–1 matched exactly for
sex and age and approximately for intelligence
quotient. As we were interested in a ‘non-acute’
schizophrenia sample with no predominating positive
symptoms, the patients were clinically stable and the
main inclusion criteria were a maximum PANSS
score of 70, a maximum Clinical Global Impressions-
Severity (CGI-S) score of 4 (moderately ill) at the
time of enrolment, and age 18–30 years. Thirty-six
patients were stabilised on atypical antipsychotics
(aripiprazole, clozapine, olanzapine, quetiapine, ris-
peridone, or ziprasidone), and three patients were
not taking antipsychotic medication. Patients had to
stay on stable pharmacological treatment throughout
the examination period (8 days), that is, dose or
medication type could not be changed. Exclusion
criteria included neurological diseases, head trauma,
and substance abuse; drug screening was used to
exclude substance abuse. Patients and HC were in a
relaxed state at the time of blood sampling, and the
room temperature was held at 21°C/70°F.
The study was approved by the ethics committee
of the Ludwig Maximilian University, and written
informed consent was obtained from all participants
before study inclusion.
Laboratory procedures
Blood samples were collected between 08:00 a.m. and
09:00 a.m. on two different days (day 1, day 8); EDTA
tubes containing aprotinin 400 IU/ml blood were used to
avoid hormone degradation. Samples were kept on ice
for up to 1 h until centrifugation at 1500×g for 15min
at 4°C. Supernatants were collected and stored at
−80°C for a maximum of 6 weeks until being assayed.
Plasma OT and AVP were assessed with commer-
cially available ELISA immunoassay kits (Catalogue
number: ADI-900-153, Enzo Life Science, Lausen,
Germany) according to the method of Taylor et al. and
the supplier’s instructions. Briefly, to determine OT the
samples were diluted fivefold to avoid matrix effects,
and the assay was performed on 100 µl. Analyses were
performed in triplicates. The intraassay coefficient of
variation (CV) was 14.9%, and the interassay CV,
determined across 10 separate runs, was 18.95%.
To determine AVP, the samples were diluted
twofold, and the assay was performed on 100 µl. The
intraassay CV was 5.9%, and the interassay CV,
determined across 10 separate runs, was 13.2%.
Assessment instruments
Schizophrenia psychopathology was assessed with
the PANSS (2); and disease severity, with the CGI
scale (42). PANSS items were divided into positive,
negative, and global domains. Moreover, we sub-
divided by the factor autistic preoccupation accord-
ing to the factor analyses by White et al. (3). The
factor autistic preoccupation is defined by the six
PANSS items poor attention (G11), preoccupation
(G15), difficulty in abstraction (N5), stereotyped
thinking (N7), disturbed volition (G13), and halluci-
nations (P3). All ratings were performed by the
same experienced senior psychiatrist (S.D.) on day 8.
Oxytocin and vasopressin levels in schizophrenia patients
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Sociodemographic characteristics were recorded;
they included information about childhood, severe
life events, number of important attached persons,
social network, and partnerships.
Statistical methods
The amount of OT and AVP measured at both
collections was investigated for stability and outliers,
and the mean level from the two measurements was
used in subsequent analyses. This was warrant-
able procedure as both OT and AVP levels were
consistent across the two measurements: OT levels did
not differ significantly between the two measurements
in either patients (mean OT1: 254.96 pg/ml, mean
OT2: 256.27 pg/ml; U = 0.641; p = 0.521) or HC
(mean OT1: 378.86 pg/ml, mean OT2: 373.06 pg/ml;
U = 0.356; p = 0.722). AVP levels also did not differ
significantly between the two measurements in either
patients (mean AVP1: 50.62 pg/ml, mean AVP2:
48.07 pg/ml; U = 0.089; p = 0.930) or HC (mean
AVP1: 65.41 pg/ml, mean AVP2: 59.62 pg/ml;
U = 1.406; p = 0.160). OT levels correlated positively
between the two measurements in the patient group
(ρ = 0.859; p<0.001*) and in the control group
(ρ = 0.963; p<0.001*). AVP levels correlated posi-
tively between the two measurements in the patient
group (ρ = 0.747; p<0.001*) and in the control group
(ρ = 0.857; p<0.001*).
Because of the skewed distributions of OT and
AVP, the rank-based Wilcoxon–Mann–Whitney test
was used to compare patients and HC. With respect
to sociodemographic variables χ2, Student’s t and
Wilxocon–Mann–Whitney tests were applied in
accordance with each variable’s scale.
The association between OT, AVP, and PANSS
items or subscores as well as other clinical and
demographic factors in patients was evaluated with
Spearman’s correlation coefficient. We used the sum
of the six PANSS items (poor attention, preoccupa-
tion, difficulty in abstraction, stereotyped thinking,
disturbed volition, and hallucinations) of the autistic
preoccupation factor as the composite score for
autistic symptoms (3). Furthermore, we performed
a linear regression analysis with OT and AVP
as the independent (predictor) variable and PANSS
scale scores as the dependent (outcome) variable to
identify the set of variables (sociodemographic and
related to the PANSS) that best described the levels
of OT and AVP in patients.
The predetermined α level was 0.05. In light of the
exploratory nature of the study, we did not perform
corrections for multiple testing. All analyses were
carried out with SPSS software version 17 for statis-
tical analyses and the graphics were generated with
the statistical software environment R 2.13.2 (43).
Results
Demographics
The schizophrenia patients and HC did not differ
with regard to age (schizophrenia patients: 24.9±
3.56 years, range 18–30; HC: 24.6± 3.06 years,
range 19–30). The patients’ mean duration of illness
was 6 years (6.2± 5.11 years, range 0–20). In the
whole group of patients, the PANSS positive score
was 10.0± 2.68 (range 7–15); the PANSS negative
score, 20.1± 6.11 (7–30); the PANSS general score,
30.8± 6.64 (17–44); and the overall PANSS total
score, 61.0± 12.06 (34–82). The PANSS autistic
preoccupation score was 12.7± 4.13 (6–20). Thirteen
patients (33%) were being treated with one anti-
psychotic; 21 (54%), with two antipsychotics; and
2 (5%), with three antipsychotics. Three patients
(8%) were not taking antipsychotic medication and
data were missing for two patients.
The schizophrenia patients had grown up signifi-
cantly more often with only one parent or not with their
parents (χ21 = 4.893; p = 0.027*) and more often
reported a severe life event (χ21 = 8.950; p = 0.003*)
compared with HC. The patients reported significantly
more often having no former or current partnerships
(χ21 = 17.628; p<0.001*). The schizophrenia group
had significantly fewer (3.2±2.19, range 0–10)
important attached persons than the HC (4.9±2.19,
range 2–10; U = 3.479; p<0.001*). Social net-
working, for example, Facebook, was used less
frequently by the schizophrenia patients (68% vs.
93%, χ21 = 8.883; p = 0.003*). Sample characteristics
are shown in Table 1.
Oxytocin and arginine-vasopressin
The schizophrenia patients had significantly lower
plasma OT levels (median 225.70 pg/ml) than the HC
(median 292.60 pg/ml; U = 2.754; p = 0.006), see
Table 2. AVP levels showed a similar trend, with lower
levels in the patient group (median 45.48 pg/ml in
schizophrenia patients and median 55.36 pg/ml in HC;
U = 1.946; p = 0.052; see Figs 1 and 2 and Table 2).
Severe life events (U = − 2.757; p = 0.006*) and
fewer important attached persons (ρ = − 0.278;
p = < 0.010*) were associated with lower OT levels.
Moreover, lower OT levels correlated with growing
up with only one parent or without parents (Kruskal-
–Wallis Test: χ23 = 13.098; p = < 0.001*). Higher
OT levels were found in participants who had
grown up with both parents. OT plasma levels did
not correlate with being in a former or current
partnership or with social networking. OT levels
did not differ significantly between patients treated
with one antipsychotic agent and those treated
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p = 1.000) and did not correlate with the number of
antipsychotics (ρ = − 0.016; p = 0.923).
Within the patient group, we found a negative
association between the PANSS negative scale score
and OT levels (ρ = − 0.413; p = 0.007*): Patients
with a high PANSS negative scale score had lower
plasma OT levels. However, this was not the
case for the PANSS positive or general scale score,
neither of which correlated with OT levels. The most
dominant ‘autistic’ symptoms ‘preoccupation’ (G15;
ρ = − 0.537; p<0.001*), ‘emotional withdrawal’ (N2,
ρ = − 0.531; p<0.001*), and ‘passive/apathetic social
withdrawal’ (N4, ρ = − 0.509; p = 0.001*) were
negatively correlated with OT levels (Fig. 3). Regres-
sion analysis with OT as the independent (predictor)
variable and PANSS negative scale score as the
dependent (outcome) variable showed a significant
association (β: −0.420; t1 = − 2.894; p = 0.006*). The
effects remained significant even after controlling
for antipsychotics, age, life events, and important
attached persons, none of which was a predicting
variable. OT levels did not predict the PANSS positive
or general score.
OT levels did not directly correlate with AVP
levels in either the patient group (ρ = 0.082;
p = 0.614) or the HC group (ρ = 0.055; p = 0.717).
Table 1. Sample characteristics
Schizophrenia patients (n = 41) Healthy controls (n = 45) Test statistic p-value
Age in years, mean (SD) 24.9 (3.56) 24.6 (3.06) t84 = 0.322 0.748
Grown up with
Both parents [n (%)] 26 (63.4%) 38 (84.4%) χ2 = 10.888 0.012*
Only father [n (%)] 2 (4.9%) 0 (0%)
Only mother [n (%)] 4 (9.8%) 6 (13.3%)
Not with parents [n (%)] 9 (22.0%) 1 (2.2%)
History of severe life events [yes, n (%)] 24 (58.5%) 12 (26.7%) χ2 = 8.953
Former partnership [yes, n (%)] 29 (70.7%) 43 (95.6%) χ2 = 9.700 0.002*
In current partnership [yes, n (%)] 11 (26.8%) 28 (62.2%) χ2 = 10.843 0.001*
No. of important attached persons, [mean (SD)] 3.2 (2.19) 4.9 (2.17) U = 3.509 < 0.001*
Participates in social networking [n (%)] 28 (68.3%) 43 (95.6%) χ2 = 11.074 0.001*
Duration of illness in years [mean (SD)] 6.2 (5.11) – – –
Age at first treatment in years [mean (SD)] 21 (3.69) – – –
PANSS positive score [mean (SD)] 10.0 (2.68) – – –
PANSS negative score [mean (SD)] 20.1 (6.11) – – –
PANSS global score [mean (SD)] 30.8 (6.64) – – –
PANSS total score [mean (SD)] 61.0 (12.06) – – –
PANSS, Positive and Negative Syndrome Scale.
Table 2. OT and AVT levels (pg/ml) in male schizophrenia patients (n = 41) and healthy controls (n = 45). Samples were obtained on two days
Group Min. 1st Qu. Median Mean 3rd Qu. Max. IQR
Patient OT 83.89 177.10 225.70 255.60 310.40 575.50 133.32
Control OT 91.34 229.80 292.60 376.00 520.20 1011.00 290.36
Patient AVP 20.38 34.93 45.48 49.35 57.28 112.50 22.36
Control AVP 14.60 41.66 55.36 62.52 77.28 178.20 35.62
1st Qu., 1st quartile; 3rd Qu., 3rd quartile; IQR, interquartile range; Max., maximum; Min., minimum.; OT, oxytocin; AVP, arginine-vasopressin.
Fig. 1. Distribution of mean oxytocin levels in schizophrenia
patients and healthy controls.
Fig. 2. Distribution of mean argenine vasopressin levels in
schizophrenia patients and healthy controls.
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AVP levels did not correlate with the PANSS
subscale scores or with life events, former or current
partnerships, social networking, or the number of
important attached persons, and regression analysis
revealed no predictive value for clinical symptoms.
Schizophrenia patients with former relationships
showed higher AVP levels than patients without
former relationships (U = 1.978; p = 0.048*). AVP
levels did not differ significantly between schizo-
phrenia patients treated with one antipsychotic agent
and those treated with more than one antipsychotic
agent (U = 1.161; p = 0.257) and did not correlate
with the number of antipsychotics (ρ = 0.157;
p = 0.346).
Discussion
The young men with schizophrenia showed lower
OT and AVP plasma levels than the HC. As our
measurements were taken on two different days and
no additional tests were performed on these days,
the levels represent the basal hormone state of
patients and controls. Patients showed lower social
functioning – defined by fewer attached persons,
fewer former and current partnerships, and less use
of social network – than HC. Moreover, patients had
more severe life events and had more often grown up
with only one parent or no parents.
Most of the other previous studies focused on OT
with regard to the performance of schizophrenia patients
in social tests. Kéri et al. (18) found a significant
difference in OT levels between their mixed-sex,
chronic schizophrenia group and HC only after a trust
experiment. However, baseline hormone changes seem
particularly relevant with regard to possible new
treatment options for schizophrenia. First studies have
tested whether adjunctive OT treatment improves
schizophrenia symptoms. Positive effects have been
demonstrated for overall symptoms (25–27,29,30),
cognition (28), social cognition (30,31), and emotion
recognition (33). One study found the greatest effects in
a reduction of negative symptoms (27).
Our study found that OT was significantly associated
with the PANSS negative symptom score. This finding
is in line with the results from Kéri et al. (18), who also
found significant associations between low OT levels
and PANSS negative symptoms. It is in line also with a
previous investigation by Sasayama et al. (16), who
found a negative correlation between CSF OT and the
negative PANSS subscale in male patients with
schizophrenia. Our finding that OT was strongly
associated mainly with the ‘autistic’ PANSS items,
such as preoccupation, emotional withdrawal, and
passive/apathetic social withdrawal, indicates that a
subgroup of schizophrenia patients with predominantly
negative symptoms may show the most changes in OT
metabolism and supports our hypothesis that the
‘autistic’ symptoms of schizophrenia are associated
with an alteration in the metabolism of the ‘attachment’
hormone. Moreover, we found an association between
lower OT levels and fewer important attached persons
and growing up without both parents, which might
define social functioning. The hypothesis is underlined
by previous findings of blunted plasma OT levels
in schizophrenic patients and an association with a
low performance in emotional recognition, an autistic
symptom (17), although these effects were found only
in patients with neuroendocrine dysfunction (polydipsia
hyponatremia). Further studies on OT as a potential
treatment option in schizophrenia, especially for
negative and autistic symptoms, should be performed
in this subgroup of patients.
Previous findings on the AVP system and schizo-
phrenia are much more limited. In an earlier study,
polydipsic hyponatremic schizophrenia patients
showed enhanced AVP and hypothalamic pituitary
Fig. 3. Correlation of Positive and Negative Syndrome Scale (PANSS) items with oxytocin Several PANSS autistic items correlated
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adrenal axis responses to stress that appeared attribut-
able to anterior hippocampal dysfunction (17). In
contrast, very recent studies demonstrated lower
AVP levels in schizophrenia patients than in HC
(20,21). Higher AVP levels were associated with
greater positive symptom severity in female
schizophrenia patients (21). Less is known about
the association between negative symptoms and AVP
levels, but recent studies demonstrated positive
effects on negative symptoms in schizophrenic
patients after intranasal administration of an AVP
analogue (37,38). In our study, we found no
association between AVP levels in schizophrenia
patients and symptom severity of positive, negative,
or autistic symptoms. However, we found lower
AVP plasma levels in male schizophrenia patients
than in HC. This finding is in line with results of
previous studies (20,21). Therapeutic use of AVP
might be discussed for schizophrenia patients – even
though we found no direct correlation between AVP
levels and clinical symptoms assessed by the PANSS
– because recent studies found many features of
schizophrenia in AVP-deficient (Brattleboro) rats
(39,40) and intranasal administration of an AVP
analogue was found to have a positive effect on
negative symptoms in schizophrenia patients (37,38).
Future studies should focus on measurements of
other AVP-related symptoms like aggression, social
cognition, and emotion recognition, because these
symptoms might not have been appropriately
reflected by the PANSS.
Our study may be limited by the fact that we did not
ask about sexual activity, which has been reported to
affect OT (44). However, we measured the hormones
on two different days (days 1 and 8), and the findings
showed nearly the same levels and no significant
difference. Another limitation is that our results might
be gender related and cannot be transferred to female
patients. We chose to study men because they show
less variation in hormone levels. Most of the patients
were on a stable therapeutic dose of one or two
antipsychotic agents; the number of antipsychotic
agents used for treatment had no effect on the OT
plasma level. This is in line with the finding of
previous studies that neuroleptic drugs did not affect
CSF OT levels in schizophrenic patients (15).
However, intake of atypical antipsychotic drugs still
might have affected OT and AVP plasma levels. So
far, it is unclear whether and how atypical
antipsychotic drugs affect the OT and AVP system.
For example, studies have found an increase and a
decrease in OT levels related to dopaminergic active
drugs (45–47). Therefore, results should be confirmed
in a drug-free sample to exclude medication effects on
hormone levels. Antipsychotics have been found not to
stimulate vasopressin release directly, but they may
stimulate it indirectly (36). Moreover, OT plasma
levels may not be representative for OT levels in the
CSF. Therefore, future studies comparing plasma and
CSF levels are required. Last, beside alterations in OT
metabolism, many roads could lead to decreased
plasma OT levels, including decreased OT synthesis,
mRNA expression, translation, and others.
Taken together our results are in line with previous
findings of lower OT and AVP levels in schizo-
phrenia patients than in HC and an inverse correlation
with symptom severity (16–21). However, some
studies did not observe such differences (13,15,16,21)
or even demonstrated opposite results (13,14,34).
This discrepancy might have different reasons. First,
comparability of the different studies is difficult,
because cohorts are inhomogeneous with respect to
gender (male, female, or mixed gender samples) and
method of measurements (plasma or CSF). Moreover,
acute psychotic illness might have affected results in
some samples, because greater positive symptoms were
related to higher plasma OT levels (20) and higher
AVP levels (21) in acute schizophrenia patients.
Therefore, lower OT and AVP plasma levels might
be specifically associated with negative symptoms
and autistic symptoms in schizophrenia. If so, OT
differences indicate that there might be a disruption in
the ability of physiological levels of OT to modulate
social cognition in schizophrenic patients. Our results
provide further support for an association between
social deficits (represented by PANSS autistic
symptoms and negative symptoms) and lower OT
levels in schizophrenia. Moreover, they support the
hypothesis that decreased AVP levels might be a
marker of biological vulnerability for psychosis, as
previously suggested (20).
We hope that this study will contribute to the future
therapeutic potential of OT and AVP in schizo-
phrenia (48). Current treatment options for the
negative and autistic symptoms of schizophrenia are
very limited and often unsatisfactory for the patient.
Therefore, especially the subgroup of schizophrenia
patients with these symptoms might eventually profit
from new or additional treatment options with
hormones.
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